2-(4-chlorophenyl)-1-(4-(7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta(d)pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one,
GDC-0068,
GDC0068,
Ipatasertib,
GDC-0068,
1001264-89-6,
Ipatasertib (GDC-0068),
GDC 0068,
UNII-524Y3IB4HQ,
RG7440,
GDC-0068 (RG7440),
524Y3IB4HQ,
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one,
CHEMBL2177390,
(2S)-2-(4-Chlorophenyl)-1-[4-[(5R,7R)-6,7-dihydro-7-hydroxy-5-methyl-5H-cyclopentapyrimidin-4-yl]-1-piperazinyl]-3-[(1-methylethyl)amino]-1-propanone,
RG-7440,
C24H32ClN5O2,
(2s)-2-(4-Chlorophenyl)-1-{4-[(5r,7r)-7-Hydroxy-5-Methyl-6,7-Dihydro-5h-Cyclopenta[d]pyrimidin-4-Yl]piperazin-1-Yl}-3-(Propan-2-Ylamino)propan-1-One,
1-Propanone, 2-(4-chlorophenyl)-1-(4-((5R,7R)-6,7-dihydro-7-hydroxy-5-methyl-5H-cyclopentapyrimidin-4-yl)-1-piperazinyl)-3-((1-methylethyl)amino)-, (2S)-,
Ipatasertib [USAN:INN],
1-Propanone, 2-(4-chlorophenyl)-1-[4-[(5R,7R)-6,7-dihydro-7-hydroxy-5-methyl-5H-cyclopentapyrimidin-4-yl]-1-piperazinyl]-3-[(1-methylethyl)amino]-, (2S)-,
AK174371,
RG 7440,
Ipatasertib (USAN/INN),
Ipatasertib; GDC-0068,
SCHEMBL191659,
GTPL7887,
CHEBI:95089,
GRZXWCHAXNAUHY-NSISKUIASA-N,
AOB87386,
EX-A2077,
BDBM50398379,
MFCD22124514,
s2808,
ZINC68250459,
AKOS025396463,
BCP9000712,
CS-0975,
DB11743,
SB16560,
NCGC00346714-01,
(2S)-2-(4-Chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta(d)pyrimidin-4-yl)piperazin-1-yl(-3-((propan-2-yl)amino)propan-1-one,
AC-28420,
AS-17027,
BC295592,
HY-15186,
QC-10488,
BCP0726000195,
AB0033076,
FT-0773211,
X6541,
J3.478.537F,
D10641,
W-5890,
(2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[e]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-one,
0RF,
AKT inhibitors,
Ipatasertib [INN],
D0I4TH,
cc-616,
A3006,
A11246,
1417449-25-2,